DynamX Bioadaptor RCT Two-Year Outcomes: Significant Advantages vs DES

Published: 15 August 2024

  • Views:

    Views Icon 617

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Recorded at EuroPCR 2024 in Paris, these interviews provide insight into the Bioadaptor RCT trial.

These interviews are supported by

Learning Objectives

  • Understand the clinical design and goal of the Bioadaptor RCT study
  • Review the clinical endpoints and results of the study at two-year follow-up
  • Discover the clinical practice implications of the study

Target Audience

  • Interventional Cardiologists
  • PCI Operators

More from this programme

Part 1

Perspective on DynamX Bioadaptor RCT Two-Year Outcomes

In this insightful interview, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) is delving into the two-year findings of the Bioadaptor RCT trial, recently presented at the EuroPCR Conference in May 2024.1 This interview will provide a comprehensive review of the trial and findings, highlighting the potential implication for the current clinical practice.

Dr Alasnag will examine the design, methodology and outcomes, offering an in-depth interpretation of the results. Additionally, Dr Alasnag will explore the clinical implications of these findings to discuss the next steps and potential impact on the future of PCI in light of the trial findings.

References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
1 session
Perspective on DynamX Bioadaptor RCT Two-Year Outcomes Watch now

Part 2

Summary of Outcomes of Bioadaptor RCT Two-Year

Dr Saito, the primary investigator of Bioadaptor RCT, shares a quick summary of the two-year outcomes presented at EuroPCR 2024. EuroPCR 2024 recognised the two-year Bioadaptor RCT results as one of the top three trial updates. Dr Saito highlights how the novel design and mechanism of action of DynamX Bioadaptor restores haemodynamic modulation to the artery, delivers sustained significant clinical benefit, establishing a new therapy and potentially a new standard of treatment for patients with CAD.1

References:
1. Bioadaptor RCT 2 year outcomes. S. Saito. EuroPCR 2024.
2 sessions
Summary of Outcomes of Bioadaptor RCT Two-Year Watch now
Summary of Outcomes of Bioadaptor RCT Two-Year (Japanese) Watch now

Faculty Biographies

Shigeru Saito

Shigeru Saito

Director of Cardiology and Catheterisation Laboratories

Dr Shigeru Saito is the Director of Cardiology and Catheterisation Laboratories, at Shonan Kamakura General Hospital in Kamakura, Japan. Dr Saito is one of the leading supporters and practitioners of transradial coronary intervention (TRI) in the world. As an evangelist for TRI, he has travelled the world to teach and demonstrate the benefits and techniques of this alternative to the femoral approach.

One of Dr Saito’s primary activities is to develop a strategy of retrograde approach in coronary angioplasty for chronic total occlusion. He serves as President of NPO International TRI Network. He serves on the editorial boards of Catheterization and Cardiovascular Interventions, Journal of Invasive Cardiology and the International Journal of Cardiology. Dr Saito is widely published in the fields of acute myocardial infarction, cardiomyopathy, coronary angioplasty and the transradial approach.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.